By targeting oncogenic drivers such as EGFR, adaptive mechanisms like Axl-driven EMT, immune checkpoints like PD-L1, and CSC-associated markers including CD133, these nanosystems can enhance tumor selectivity, improve drug accumulation, overcome resistance, and synergize with immunotherapy. This evidence concerns the gene AXL and neoplasm.